{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:35:40Z","timestamp":1791228940494,"version":"4.1.0"},"reference-count":26,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,10,13]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Myeloid\/lymphoid neoplasms with eosinophilia are driven by aberrant tyrosine kinases in pluripotent cells and display variable phenotypes. FGFR-driven hematolymphoid neoplasms are targetable by TKI inhibitors such as ponatinib; studies of specific FGFR inhibitors are ongoing.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019001282","type":"journal-article","created":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T19:57:23Z","timestamp":1602619043000},"page":"4924-4928","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":17,"title":["Diagnosis and treatment of mixed phenotype (T-myeloid\/lymphoid) acute leukemia with novel ETV6-FGFR2 rearrangement"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1509-2158","authenticated-orcid":false,"given":"Timothy","family":"Carll","sequence":"first","affiliation":[{"name":"Department of Pathology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0296-8686","authenticated-orcid":false,"given":"Anand","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, University of Chicago, Chicago, IL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4070-1819","authenticated-orcid":false,"given":"Benjamin","family":"Derman","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, University of Chicago, Chicago, IL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hyjek","sequence":"additional","affiliation":[{"name":"Department of Pathology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6799-8755","authenticated-orcid":false,"given":"Angela","family":"Lager","sequence":"additional","affiliation":[{"name":"Department of Pathology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6228-8431","authenticated-orcid":false,"given":"Pankhuri","family":"Wanjari","sequence":"additional","affiliation":[{"name":"Department of Pathology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0958-3295","authenticated-orcid":false,"given":"Jeremy","family":"Segal","sequence":"additional","affiliation":[{"name":"Department of Pathology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4027-4124","authenticated-orcid":false,"given":"Olatoyosi","family":"Odenike","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, University of Chicago, Chicago, IL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8063-5046","authenticated-orcid":false,"given":"Shiraz","family":"Fidai","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, John H. Stroger Hospital of Cook County, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2160-9689","authenticated-orcid":false,"given":"Daniel","family":"Arber","sequence":"additional","affiliation":[{"name":"Department of Pathology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,10,13]]},"reference":[{"issue":"1","key":"2020101311363913700_B1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"issue":"14","key":"2020101311363913700_B2","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"issue":"11","key":"2020101311363913700_B3","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood-2010-10-314682","article-title":"Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification","volume":"117","author":"Matutes","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2020101311363913700_B4","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3109\/10428194.2011.621562","article-title":"High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML)","volume":"53","author":"Larson","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"2020101311363913700_B5","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.critrevonc.2017.02.018","article-title":"FGFR a promising druggable target in cancer: molecular biology and new drugs","volume":"113","author":"Porta","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"2020101311363913700_B6","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2020101311363913700_B7","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1182\/blood.V96.2.699","article-title":"ZNF198-FGFR1 transforming activity depends on a novel proline-rich ZNF198 oligomerization domain","volume":"96","author":"Xiao","year":"2000","journal-title":"Blood"},{"issue":"6","key":"2020101311363913700_B8","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1182\/blood-2016-10-695973","article-title":"Myeloid neoplasms with eosinophilia","volume":"129","author":"Reiter","year":"2017","journal-title":"Blood"},{"issue":"23","key":"2020101311363913700_B9","first-page":"8371","article-title":"Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation","volume":"61","author":"Yagasaki","year":"2001","journal-title":"Cancer Res"},{"issue":"2","key":"2020101311363913700_B10","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0092-8674(94)90322-0","article-title":"Fusion of PDGF receptor \u03b2 to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation","volume":"77","author":"Golub","year":"1994","journal-title":"Cell"},{"issue":"55","key":"2020101311363913700_B11","doi-asserted-by":"crossref","first-page":"6524","DOI":"10.1038\/sj.onc.1204045","article-title":"Proteins of the ETS family with transcriptional repressor activity","volume":"19","author":"Mavrothalassitis","year":"2000","journal-title":"Oncogene"},{"issue":"5","key":"2020101311363913700_B12","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1073\/pnas.94.5.1949","article-title":"Functional characterization of ETV6 and ETV6\/CBFA2 in the regulation of the MCSFR proximal promoter","volume":"94","author":"Fears","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2020101311363913700_B13","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1053\/j.seminhematol.2017.04.005","article-title":"ETV6 in hematopoiesis and leukemia predisposition","volume":"54","author":"Hock","year":"2017","journal-title":"Semin Hematol"},{"issue":"2","key":"2020101311363913700_B14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s12185-017-2259-4","article-title":"Germline ETV6 mutations and predisposition to hematological malignancies","volume":"106","author":"Feurstein","year":"2017","journal-title":"Int J Hematol"},{"issue":"5","key":"2020101311363913700_B15","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood.V93.5.1707","article-title":"TEL\/PDGFbetaR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor","volume":"93","author":"Tomasson","year":"1999","journal-title":"Blood"},{"issue":"4","key":"2020101311363913700_B16","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00277-008-0603-8","article-title":"BMI-1 expression is enhanced through transcriptional and posttranscriptional regulation during the progression of chronic myeloid leukemia","volume":"88","author":"Bhattacharyya","year":"2009","journal-title":"Ann Hematol"},{"issue":"8","key":"2020101311363913700_B17","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.leukres.2012.04.010","article-title":"ETV6 fusion genes in hematological malignancies: a review","volume":"36","author":"De Braekeleer","year":"2012","journal-title":"Leuk Res"},{"issue":"5","key":"2020101311363913700_B18","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/ng.3253","article-title":"Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia","volume":"47","author":"Noetzli","year":"2015","journal-title":"Nat Genet"},{"issue":"2","key":"2020101311363913700_B19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41571-018-0115-y","article-title":"Fibroblast growth factor receptors as treatment targets in clinical oncology","volume":"16","author":"Katoh","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"2020101311363913700_B20","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood-2018-99-110388","article-title":"Interim results from Fight-203, a phase 2, open-label, multicenter study evaluating the efficacy and safety of pemigatinib (INCB054828) in patients with myeloid\/lymphoid neoplasms with rearrangement of fibroblast growth factor receptor 1 (FGFR1)","volume":"132","author":"Verstovsek","year":"2018","journal-title":"Blood"},{"issue":"3","key":"2020101311363913700_B21","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1158\/1535-7163.MCT-11-0450","article-title":"Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models","volume":"11","author":"Gozgit","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"2020101311363913700_B22","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2147\/OTT.S189391","article-title":"Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies","volume":"12","author":"Tan","year":"2019","journal-title":"OncoTargets Ther"},{"issue":"5","key":"2020101311363913700_B23","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O\u2019Hare","year":"2009","journal-title":"Cancer Cell"},{"issue":"1","key":"2020101311363913700_B24","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/15384047.2015.1108492","article-title":"Antitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutations","volume":"17","author":"Kim","year":"2016","journal-title":"Cancer Biol Ther"},{"issue":"4","key":"2020101311363913700_B25","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/leu.2015.136","article-title":"Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia","volume":"30","author":"Khodadoust","year":"2016","journal-title":"Leukemia"},{"issue":"20","key":"2020101311363913700_B26","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/19\/4924\/1761849\/advancesadv2019001282.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/19\/4924\/1761849\/advancesadv2019001282.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T19:57:45Z","timestamp":1602619065000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/19\/4924\/464329\/Diagnosis-and-treatment-of-mixed-phenotype"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,13]]},"references-count":26,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2020,10,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019001282","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,13]]}}}